Journal of Isfahan Medical School

Journal of Isfahan Medical School

Effectiveness of 0.4% Amphotericin gel along with the intralesional injection of Glucantime compared with intralesional injection of Glucantime alone for acute cutaneous leishmaniasis treatment

Document Type : Original Article(s)

Authors
1 Skin diseases and leishmaniasis research center, Department of dermatology, Isfahan university of medical sciences, Isfahan, Iran
2 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Skin diseases and leishmaniasis research center, Isfahan university of medical sciences, Isfahan, Iran
4 Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
10.48305/jims.2026.43566.2360
Abstract
Background: The aim of the present study was to investigate the effectiveness of topical amphotericin gel on leishmaniasis cutaneous lesions by adding this drug to the standard treatment of leishmaniasis.
Methods: This randomized clinical trial was conducted on two groups of patients. The first group was treated with weekly intralesional injections of glucantime alone. The second group was treated weekly with intralesional injections of glucantime and 0.4% amphotericin topical gel daily.
Findings: The mean (standard deviation) age of 32 participants in the study was 33.4 (14.8) and 29 (72.5%) of them were men. 70% of patients in the glucantime alone group and 80% of patients in the amphotericin group showed complete cure. There was no significant difference between the two groups in terms of the outcome by examining changes in size and induration of the lesions (P>0.05). Results of repeated measures revealed that the effect of the course was significant for the change in the size of the lesions in the two drug groups (P=0.36).
Conclusion: The combination of amphotericin gel with the standard treatment of cutaneous leishmaniasis causes a slight increase in the effectiveness of the treatment, although this slight improvement was not significant in our study.

Highlights

Nazila Poostiyan: Google Scholar, PubMed

Zabihollah Shahmoradi: Google Scholar

Setayesh Sindarreh: Google Scholar, PubMed

Keywords

Subjects



Articles in Press, Accepted Manuscript
Available Online from 07 February 2026

  • Receive Date 18 March 2025
  • Accept Date 21 January 2026